Drug intelligence / Profile preview

glargine + regular insulin + neutral protamine hagedorn insulin

Development stage: Unknown
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

This is a combination of three different insulin types used in diabetes management. It includes insulin glargine (a long-acting insulin), regular insulin (a short-acting insulin), and neutral protamine hagedorn insulin (NPH, an intermediate-acting insulin). These insulins are not typically combined in a single formulation but may be prescribed separately as part of a comprehensive insulin regimen to provide basal, prandial, and intermediate coverage for optimal glycemic control in diabetes patients.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on glargine + regular insulin + neutral protamine hagedorn insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glargine + regular insulin + neutral protamine hagedorn insulin.

Explore the full profile